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Background
Patients with chronic obstructive pulmonary disease
(COPD) often present with symptoms equivalent to an
acute coronary syndrome (ACS) and slightly elevated high
sensitive troponine in the observational range (hsTnT
14-53 ng/l). While this cannot differentiate between cor-
onary or pulmonary origin of myocardial damage it neces-
sitates further investigation since it has prognostic impact.
Comorbidity of COPD and coronary heart disease is fre-
quent and risk factors are also congruent. In this acute set-
ting, a safe, and reliable test to identify coronary problems
is of great value. Non-invasive assessment of these patients
is hampered by low echocardiographic imaging quality
due to pulmonary emphysema and by the bronchospasmic
effect of adenosine. With the new vasodilatator regadeno-
son, stress-MRI is possible in patients with COPD.
The aim of this study was to evaluate the value of
regadenoson stress MRI in patients with known COPD
and low troponine values.
Methods
Ten patients (66±18 yo) with COPD GOLD grade I-III pre-
senting with ACS and elevated hsTnT in the observational
range (23±8 ng/l) were enrolled. Prior to coronary catheter-
ization, they underwent cMRI with regadenoson-stress (400
µg i.v. bolus). Scans were conducted on a Philips Achieva
1.5 T MRI, including CINE-sequences, T2-imaging, late
enhancement imaging, pulmonary angiography as well as
rest and stress myocardial perfusion measurements. All
Patients received pulmonary function testing before and
after regadenoson and coronary angiography after cMRI.
Results
All cMRI scans were conducted without any adverse effect.
Pulmonary function testing revealed no deterioration after
regadenoson (FEV1 pre and post MRI: 66% and 68%).
Quality of the scans remained unhampered by the
emergency management. Regadenoson elevated heart
rate and rate-pressure-product significantly by 29%. In
three patients, stress cMRI detected myocardial ische-
mia. In all these patients, coronary catheterization
revealed relevant coronary stenoses necessitating inter-
vention in the respective vessel predicted by cMRI. All
patients without myocardial ischemia in cMRI had no
coronary stenosis in catheterization. Positive and nega-
tive predictive values of cMRI with regadenoson-stress
were 100% in our population.
Conclusions
Cardiac stress MRI proved safe in the acute setting of
ACS management. Regadenoson did not affect pulmon-
ary function. cMRI delivered reliable results with com-
parable quality to non emergency settings, showing
positive and negative predictive values of 100% when
determining the need for coronary revascularisation and
predicting the target vessel.
This method could influence the future management
of patients with COPD ACS and slightly elevated hsTnT
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